217 related articles for article (PubMed ID: 23382971)
1. Sodium valproate alleviates neurodegeneration in SCA3/MJD via suppressing apoptosis and rescuing the hypoacetylation levels of histone H3 and H4.
Yi J; Zhang L; Tang B; Han W; Zhou Y; Chen Z; Jia D; Jiang H
PLoS One; 2013; 8(1):e54792. PubMed ID: 23382971
[TBL] [Abstract][Full Text] [Related]
2. Polyglutamine-expanded ataxin-3 impairs long-term depression in Purkinje neurons of SCA3 transgenic mouse by inhibiting HAT and impairing histone acetylation.
Chou AH; Chen YL; Hu SH; Chang YM; Wang HL
Brain Res; 2014 Oct; 1583():220-9. PubMed ID: 25139423
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of valproic acid treatment in SCA3/MJD patients.
Lei LF; Yang GP; Wang JL; Chuang DM; Song WH; Tang BS; Jiang H
Parkinsonism Relat Disord; 2016 May; 26():55-61. PubMed ID: 26997655
[TBL] [Abstract][Full Text] [Related]
4. Sodium valproate increases activity of the sirtuin pathway resulting in beneficial effects for spinocerebellar ataxia-3 in vivo.
Watchon M; Luu L; Robinson KJ; Yuan KC; De Luca A; Suddull HJ; Tym MC; Guillemin GJ; Cole NJ; Nicholson GA; Chung RS; Lee A; Laird AS
Mol Brain; 2021 Aug; 14(1):128. PubMed ID: 34416891
[TBL] [Abstract][Full Text] [Related]
5. HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3.
Chou AH; Chen SY; Yeh TH; Weng YH; Wang HL
Neurobiol Dis; 2011 Feb; 41(2):481-8. PubMed ID: 21047555
[TBL] [Abstract][Full Text] [Related]
6. Lithium chloride alleviates neurodegeneration partly by inhibiting activity of GSK3β in a SCA3 Drosophila model.
Jia DD; Zhang L; Chen Z; Wang CR; Huang FZ; Duan RH; Xia K; Tang BS; Jiang H
Cerebellum; 2013 Dec; 12(6):892-901. PubMed ID: 23812869
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of NF-κB in astrocytes is sufficient to delay neurodegeneration induced by proteotoxicity in neurons.
Li YX; Sibon OCM; Dijkers PF
J Neuroinflammation; 2018 Sep; 15(1):261. PubMed ID: 30205834
[TBL] [Abstract][Full Text] [Related]
8. Divalproex sodium modulates nuclear localization of ataxin-3 and prevents cellular toxicity caused by expanded ataxin-3.
Wang ZJ; Hanet A; Weishäupl D; Martins IM; Sowa AS; Riess O; Schmidt T
CNS Neurosci Ther; 2018 May; 24(5):404-411. PubMed ID: 29318784
[TBL] [Abstract][Full Text] [Related]
9. Valproic acid attenuates the suppression of acetyl histone H3 and CREB activity in an inducible cell model of Machado-Joseph disease.
Lin XP; Feng L; Xie CG; Chen DB; Pei Z; Liang XL; Xie QY; Li XH; Pan SY
Int J Dev Neurosci; 2014 Nov; 38():17-22. PubMed ID: 25068645
[TBL] [Abstract][Full Text] [Related]
10. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
Li X; Liu H; Fischhaber PL; Tang TS
Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
[TBL] [Abstract][Full Text] [Related]
11. Treatment with sodium butyrate induces autophagy resulting in therapeutic benefits for spinocerebellar ataxia type 3.
Watchon M; Robinson KJ; Luu L; An Y; Yuan KC; Plenderleith SK; Cheng F; Don EK; Nicholson GA; Lee A; Laird AS
FASEB J; 2024 Jan; 38(2):e23429. PubMed ID: 38258931
[TBL] [Abstract][Full Text] [Related]
12. Urine levels of the polyglutamine ataxin-3 protein are elevated in patients with spinocerebellar ataxia type 3.
Koike Y; Jansen-West KR; Hanna Al-Shaikh R; Carlomagno Y; Song Y; Dunmore JA; LeDoux MS; Friedman JH; Pena AB; Uitti RJ; Zaremba J; van Gerpen JA; Pfeiffer RF; Veerappan V; Aiba I; Hashimoto R; Giles SS; Shah JS; Tipton PW; Huang JF; Wierenga KJ; Aasly J; Fryer JD; Petrucelli L; Wszolek ZK; Prudencio M
Parkinsonism Relat Disord; 2021 Aug; 89():151-154. PubMed ID: 34303201
[TBL] [Abstract][Full Text] [Related]
13. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL
Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of PNKP by mutant ATXN3 triggers apoptosis by activating the DNA damage-response pathway in SCA3.
Gao R; Liu Y; Silva-Fernandes A; Fang X; Paulucci-Holthauzen A; Chatterjee A; Zhang HL; Matsuura T; Choudhary S; Ashizawa T; Koeppen AH; Maciel P; Hazra TK; Sarkar PS
PLoS Genet; 2015 Jan; 11(1):e1004834. PubMed ID: 25590633
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis of SCA3 and implications for other polyglutamine diseases.
McLoughlin HS; Moore LR; Paulson HL
Neurobiol Dis; 2020 Feb; 134():104635. PubMed ID: 31669734
[TBL] [Abstract][Full Text] [Related]
16. Toward understanding Machado-Joseph disease.
Costa Mdo C; Paulson HL
Prog Neurobiol; 2012 May; 97(2):239-57. PubMed ID: 22133674
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological Therapies for Machado-Joseph Disease.
Duarte-Silva S; Maciel P
Adv Exp Med Biol; 2018; 1049():369-394. PubMed ID: 29427114
[TBL] [Abstract][Full Text] [Related]
18. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.
Barbetti V; Gozzini A; Cheloni G; Marzi I; Fabiani E; Santini V; Dello Sbarba P; Rovida E
Epigenetics; 2013 Feb; 8(2):210-9. PubMed ID: 23321683
[TBL] [Abstract][Full Text] [Related]
19. Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to Therapeutics.
Paulino R; Nóbrega C
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108570
[TBL] [Abstract][Full Text] [Related]
20. A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3.
Chen ZS; Huang X; Talbot K; Chan HYE
Cell Death Dis; 2021 Feb; 12(2):136. PubMed ID: 33542212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
